Lung Cancer Stage Four 10 Years Cancer-Free Through Non-Toxic Issels Integrative Immunotherapy - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Lung Cancer Stage Four 10 Years Cancer-Free Through Non-Toxic Issels Integrative Immunotherapy Recurrent cancer responds to advanced Alternative Cancer Treatment


Lung Cancer Stage Four 10 Years Cancer-Free Through Non-Toxic Issels Integrative Immunotherapy

Recurrent cancer responds to advanced Alternative Cancer Treatment

PR Newswire

SCOTTSDALE, Ariz., May 14, 2014 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment 

While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.

Issels Integrative Immunotherapy distinguishes itself decisively from mere vaccine administration by integrating specific autologous cancer vaccines, such as Dendritic Cell Vaccine, as well as autologous Lymphokine-Activated Killer (LAK) Cells and activated autologous Natural Killer (NK) Cells, which work on the cellular level of the immune system, into a comprehensive immunobiologic core treatment addressing the tumor microenvironment. The Issels strategy enhances the body's complex defense mechanisms, potentiating the efficacy of vaccine and cell therapies, as seen in the case of Jim Gibson.

In March 2003, Jim Gibson commenced the non-toxic Issels Integrative Immunotherapy including dendritic cell vaccine for his recurring small cell lung cancer, which is the most lethal kind of all lung cancers. After 4 weeks of exclusive Issels Immunotherapy he achieved complete tumor remission and is still cancer free and very active 10 years later without any standard therapy.

Nicole Tupper describes her experience with solely using Issels immunobiologic core treatment for her metastatic adenocarcinoma of the appendix: "I found Issels as a last resort. When I came here, I was a mess...and all of a sudden I started making leaps and bounds. In my last ultrasound my 12-centimeter tumor completely disappeared and all my other abdominal tumors reduced to less than half."

Nicole underwent the Issels immunobiologic core treatment at the Issels U.S. out-patient facility, where patients can also receive advanced genetically targeted cancer therapies.

The Issels medical team brings decades of expertise in providing highly personalized comprehensive immunotherapy programs. Vaccine and cell therapies are administered at the most modern facility of the largest private hospital network of 22 hospitals in Mexico, which meets the highest U.S. and international standards. It is the only full-service hospital in Mexico offering integrative medicine. Visit the Issels website www.issels.com to learn more about the Issels treatment programs and facilities, or watch more videos of patient testimonials.

 

Issels Integrative Oncology w/ cancer vaccines achieves long-term remission of advanced cancers

 

Patients and their companions stay in spacious and comfortable suites, where they have immediate access to physicians
               and health care professionals in a full-service hospital

 

Hospital Lobby

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment

SOURCE Issels Foundation

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here